Literature DB >> 10607252

Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha.

M Gerotto1, F Dal Pero, D G Sullivan, L Chemello, L Cavalletto, S J Polyak, P Pontisso, D R Gretch, A Alberti.   

Abstract

Resistance of the hepatitis C virus (HCV) to interferon-alpha (IFN-alpha) therapy in patients with hepatitis C may be genetically controlled by an IFN sensitivity-determining region (ISDR) within the non-structural 5A (NS5A) gene. To assess whether HCV 1b strains carrying a 'resistant' type of ISDR are selected during unsuccessful IFN therapy, we analysed the evolution of the NS5A quasispecies, as detected by the clonal frequency analysis technique, and of the ISDR sequence by nucleotide sequence determination, in 11 patients showing no virological response during two consecutive cycles of IFN-alpha therapy. IFN-resistant patients had a homogeneous ISDR quasispecies with sequences identical to those described as 'resistant-' or 'intermediate-' type ISDR. After retreatment with IFN, further selection towards a homogeneous viral population was observed and 10 out of 11 patients had only one variant of HCV with no or just one single amino acid mutation within the ISDR sequence. Treatment and retreatment with IFN was associated in our non-responder patients with evolution of the ISDR quasispecies towards a rather homogeneous viral population carrying a conserved or minimally mutated ISDR motif, supporting the idea that this motif may be relevant for IFN resistance in HCV 1b-infected individuals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10607252     DOI: 10.1046/j.1365-2893.1999.00166.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  7 in total

1.  Analysis of mutations in the core and NS5A genes of hepatitis C virus in non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Niwat Maneekarn
Journal:  Virusdisease       Date:  2016-01-18

Review 2.  Short-term therapy for patients with hepatitis C virus genotype 2 or 3 infection.

Authors:  Olav Dalgard; Alessandra Mangia
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.

Authors:  J Nousbaum; S J Polyak; S C Ray; D G Sullivan; A M Larson; R L Carithers; D R Gretch
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

4.  Comparison of amplification enzymes for Hepatitis C Virus quasispecies analysis.

Authors:  Stephen J Polyak; Daniel G Sullivan; Michael A Austin; James Y Dai; Margaret C Shuhart; Karen L Lindsay; Herbert L Bonkovsky; Adrian M Di Bisceglie; William M Lee; Chihiro Morishima; David R Gretch
Journal:  Virol J       Date:  2005-04-22       Impact factor: 4.099

5.  Hepatitis C virus nonstructural protein 5A inhibits thapsigargin-induced apoptosis.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Shingo Nakamoto; Takaji Wakita; Hiroshi Shirasawa; Osamu Yokosuka
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

6.  Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.

Authors:  Thomas J Chambers; Xiaofeng Fan; Deborah A Droll; Edgardo Hembrador; Tiffany Slater; Michael W Nickells; Lynn B Dustin; Adrian M Dibisceglie
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Analyzing the Effects of Pretreatment Diversity on HCV Drug Treatment Responsiveness Using Bayesian Partition methods.

Authors:  Yao Fu; Gang Chen; Xuan Guo; Jing Zhang; Yi Pan
Journal:  J Bioinform Proteom Rev       Date:  2015-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.